AI assistant
Teva Pharmaceutical Industries Ltd. — Director's Dealing 2024
Mar 7, 2024
7082_rns_2024-03-07_e61dd702-cdf1-4271-8bcc-0c511d294333.pdf
Director's Dealing
Open in viewerOpens in your device viewer
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
OMB APPROVAL 3235-0287 OMB Number: Estimated average burden hours per response ... 0.5
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
(Print or Type Responses)
| 1. Name and Address of Reporting Person Drapé Eric |
2. Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Limited TEVA |
5. Relationship of Reporting Person(s) to Issuer (Check all applicable) 10% Owner Director |
||||
|---|---|---|---|---|---|---|
| (Last) (First) (Middle) C/O Teva Pharmaceutical Industries Ltd. 124 Dvora HaNevi'a St., |
3. Date of Earliest Transaction (Month/Day/Year) 03/05/2024 |
Officer (give title below) Other (specify below) Executive VP Global Operations |
||||
| (Street) Tel Aviv, L3 6944020 (City) (State) (Zip) |
4. If Amendment, Date Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
| l .Title of Security | 2. Transaction | 2A. Deemed | 3. Transaction | 4. Securities Acquired | 5. Amount of Securities Beneficially | 7. Nature | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Instr. 3) | Date | 「 Execution Date, if Code | (A) or Disposed of (D) | Owned Following Reported | Ownership of Indirect | |||||
| (Month/Day/Year) | any | (Instr. 8) | (Instr. 3, 4 and 5) | Transaction(s) | Form: | Beneficial | ||||
| (Month/Day/Year) | (Instr. 3 and 4) | Direct (D) Ownership | ||||||||
| or Indirect (Instr. 4) | ||||||||||
| (A) or | (1) | |||||||||
| Code | Amount | D | Price | (Instr. 4) | ||||||
| 'Ordinary Shares (1) | 03/05/2024 | M | 22,576 | A | (2) | 90,689 (3) | D | |||
| 'Ordinary Shares (1) | 03/05/2024 | M | 55.226 | A | (2) | 145.915 (3) | D |
| 1. Title of Derivative Security (Instr. 3) |
2 Conversion Date Price of Derivative Security |
3. Transaction or Exercise (Month/Day/Year) any |
3A. Deemed Execution Date, if (Month/Day/Year) (Instr. 8) |
4. Code |
5. Number Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) |
6. Date Exercisable Transaction of Derivative and Expiration Date (Month/Day/Year) |
7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
Security (Instr. 5) |
8. Price of 9. Number of Derivative Derivative Securities Beneficially Owned Following Reported Transaction(s) (I) (Instr. 4) |
10 Ownership of Indirect Form of Security: Direct (D) or Indirect (Instr. 4) |
11. Nature Beneficial Derivative Ownership (Instr. 4) |
|||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Code | (A) | (D) | Date Exercisable Date |
Expiration | Title | Amount or Number of Shares |
||||||||
| Restricted Share Units |
(2) | 03/05/2024 | M | 22,576 | (4) | (4) | Ordinary Shares |
22,576 | \$ 0 | 22,576 | D | |||
| Restricted Share Units |
(2) | 03/05/2024 | M | 55,226 | (2) | (5) | Ordinary 55,226 Shares |
\$ 0 | 0 | D |
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
Explanation of Responses:
-
- The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
-
- Each restricted share unitingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Committer, the cash vale of one ordinary share.
-
- Annount relieve of 9,815 Ordinary Shares by the Reporting Person, as reported in a Form 4 filed on Mach 1, 2024, which was inader to becauntes beneficially owned by the Reporting Person following the transactions reported in a Form 4 filed on March 5, 2024.
-
- Restricted share mits were granted on March 5, 2022, Mach 5, 2022, Mach 5, 2024 and 22,576 vesting on March 5, 2025.
-
- Restricted share units were granted on January 30, 2024 pursuant to the satisfaction of performance criteria and vested on March 5, 2024.
Signatures
/s/ Dov Bergwerk as attorney-in-fact for Eric Drape 03/07/2024
Signature of Reporting Person
Date
Reminder: Report on a separate line for each class of securities beneficially owned directly.
- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 18tf(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of in this form are not required to respond unless the form displays a currently valid OMB Number.